Hinge Health, Inc. (HNGE)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NYSE
Market Cap: $9.38B
Last updated: Nov 17, 2026 at 11:06 AM ET
Hinge Health, Inc. (HNGE) P/E Ratio & Valuation Multiples
Hinge Health (HNGE) trades at 56.9x trailing earnings and 12.2x sales. Its forward P/E is 37.5x. The median P/E across 7 similar companies is 35.0x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 51.7% higher over the next year. Its free cash flow yield is 3.2%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 56.9x |
| Forward P/E | 37.5x |
| Price to sales | 12.2x |
| Price to book | 32.8x |
| EV/EBITDA | 39.6x |
| Price to FCF | 31.1x |
|---|---|
| EV/FCF | 30.4x |
| PEG | N/A |
| FCF yield | 3.2% |
As of Nov 17, 2026
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About HNGE
What is HNGE's forward P/E ratio?
Hinge Health has a forward P/E ratio of 37.5x.
Is HNGE stock overvalued?
GNG's valuation label for HNGE is Overvalued. Its P/E of 56.9x compares with a median of 35.0x across 7 similar companies.
What is HNGE's price to sales ratio?
Hinge Health has a price to sales ratio of 12.2x.
HNGE pages: Overview, Forecast, Valuation, Competitors